TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

Allogeneic Hematopoietic Cell Transplantation Clinical Trial

Official title:
Safety and Efficacy of TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders in Children and Adolescent/Young Adult Patients

Status Terminated

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic selection device (Miltenyi Biotec).

Clinical Trial Description

Acute graft versus host disease (GVHD) remains a significant cause of morbidity and mortality and is the biggest barrier to successful allogeneic hematopoietic cell transplantation (HSCT) outcomes. Improved methods of acute GVHD prevention are needed. TCRαβ+/CD19+ depletion of allogeneic hematopoietic stem cell products offers an opportunity to limit the risk of acute GVHD by removing TCRαβ+ T cells and CD19+ B cells which participate in acute GVHD initiation and perpetuation. The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). ;

Study Design

Related Conditions & MeSH terms

Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Details

NCT number	NCT04088760
Study type	Interventional
Source	Children's Hospital Medical Center, Cincinnati
Contact
Status	Terminated
Phase	Phase 2
Start date	September 16, 2019
Completion date	September 3, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03678493` - A Study of FMT in Patients With AML Allo HSCT in Recipients	Phase 2
Terminated	`NCT04117477` - Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients	Phase 2
Completed	`NCT03302754` - Precision Dosing of Alemtuzumab	N/A
Not yet recruiting	`NCT02506231` - The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome	Phase 2/Phase 3
Recruiting	`NCT04332341` - Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation	Early Phase 1
Recruiting	`NCT05501756` - Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation	Phase 2
Completed	`NCT00888316` - Iron Overload in Patients Undergoing Donor Stem Cell Transplant	N/A